CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
EP547 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05525520
NCT05525520Phase 2Completed
CompareCT.gov

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Escient Pharmaceuticals, Inc·interventional·Posted Sep 1, 2022·Updated Jul 31, 2025

In Brief

A Phase 2 clinical trial evaluating EP547 and Placebo for Pruritus. Completed, enrolled 62 participants across 52 sites in 8 countries.

Detailed Summary

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus
CountriesBelgium, Canada, France, Israel, Netherlands, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedSep 1, 2022
Enrollment StartOct 6, 2022
Primary CompletionJul 17, 2024
Study CompletionSep 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.8 years ago

Interventions

EP547drug

Once daily

Placebodrug

Once daily